Shots:
- Pfizer & BioNTech reports that the MHRA in the UK has granted a temporary authorization for the EU for BNT162b2 against COVID-19. The distribution of vaccine will be prioritized according to the populations identified in guidance from the JCVI
- The MHRA’s decision is based on a rolling submission, including data from the P-III study, demonstrating 95% efficacy in participants without & with/ out prior SARS-CoV-2 infection, in each case measured from 7 days after the second dose
- This marks the first EUA following a WW P-III trial of a vaccine to combat the pandemic. The companies are anticipating further regulatory decisions across the globe in Dec’2020
Click here to read full press release/ article | Ref: Pfizer | Image: The Jakarta Post
The post Pfizer & BioNTech Receives MHRA’s EUA for BNT162b2 Against COVID-19 first appeared on PharmaShots.
